Teriparatide Tablets is an oral form of parathyroid hormone analogue (PTH 1-34), used for the treatment of osteoporosis. It mimics the activity of the body's natural parathyroid hormone, specifically promoting the proliferation and differentiation of osteoblasts, significantly stimulating new bone formation, thereby increasing bone density, improving bone microstructure, and reducing the risk of fractures. Unlike traditional anti-absorption drugs, this product is a bone-forming agent, and is particularly suitable for patients with a history of fractures or multiple risk factors for fractures, who have not responded well to other treatments or are intolerant to them, and have severe osteoporosis. Common precautions include the need to use under the guidance of a doctor and paying attention to possible adverse reactions.
|
|
|
Teriparatide Powder COA
Technological breakthroughs and challenges
Technological Breakthroughs
Nanocarrier technology
Encapsulating teriparatide through nanocarriers such as liposomes and polymer micelles can significantly improve the stability and bioavailability of the drug. For example, after the surface of exosomes was grafted with succinylated ε -polylysine, the intestinal wall permeability of teriparatide was significantly enhanced, thereby improving the oral absorption efficiency. Nanocarriers can not only protect drugs from degradation by gastrointestinal enzymes, but also achieve targeted delivery by regulating particle size and surface properties, reducing the distribution of drugs in non-target tissues and lowering systemic toxicity.
Chemical modification technology
PEGylation is a key technology for improving the stability of teriparatide. By grafting polyethylene glycol chains onto the surface of drug molecules, a protective barrier can be formed, reducing the degradation of drugs by gastric acid and protease, and simultaneously prolonging the circulation time of drugs in the body. This modification can also reduce the immunogenicity of the drug and improve the tolerance of patients.
Innovation in formulation form
At present, the formulation forms of oral teriparatide include exosome-encapsulated preparations, nanoparticle preparations and microsphere preparations, etc. For instance, the exosome-encapsulated teriparatide preparation developed by Nanjing Kangzhou Pharmaceutical has entered the clinical trial stage. By optimizing the surface modification of exosomes, it has significantly enhanced the intestinal wall permeability and bioavailability of the drug. In addition, sustained-release microsphere preparations achieve slow drug release by encapsulating teriparatide in biodegradable polymer materials, prolonging the duration of action and reducing the frequency of administration.
Technical Challenges
Low bioavailability
Despite the use of nanocarriers and chemical modification techniques, the bioavailability of oral teriparatide is still much lower than that of injectable dosage forms. Factors such as gastric acid, protease and mucus layer in the gastrointestinal tract can significantly reduce the absorption efficiency of drugs. Therefore, how to further improve the intestinal wall permeability and stability of the drug remains the core challenge in the research and development of oral teriparatide.
Poor stability of the preparation
The stability of oral preparations in the gastrointestinal tract is another key issue. Gastric acid and protease may cause drug degradation, and the preparation also needs to remain stable during storage and transportation. Therefore, it is necessary to develop new stabilizers or packaging materials to protect drugs from the influence of environmental factors.
Clinical trials are difficult
Clinical trials of oral teriparatide require large-scale and long-term follow-up to verify its efficacy and safety. In particular, it is necessary to conduct head-to-head comparisons with injection dosage forms to evaluate their relative efficacy and safety. In addition, clinical trials also need to take into account factors such as patient compliance and adverse reaction monitoring, which increases the complexity and cost of the research.
Safety and tolerance
Oral teriparatide needs to ensure that while improving bioavailability, it does not increase the risk of adverse reactions. For example, hypercalcemia is one of the possible adverse reactions during the treatment with teriparatide. Oral preparations need to better control the blood calcium level to avoid the occurrence of hypercalcemia. In addition, it is necessary to assess the irritability of the drug to the gastrointestinal tract to ensure the patient's tolerance.
Future Outlook
Despite numerous challenges, significant progress has been made in the research and development of oral teriparatide. In the future, with the continuous advancement of nanotechnology, chemical modification techniques and formulation processes, the bioavailability and stability of oral teriparatide are expected to be further improved. Meanwhile, through large-scale clinical trials to verify its efficacy and safety, oral teriparatide is expected to become a new option for the treatment of osteoporosis, providing patients with more convenient and effective treatment plans.
Teriparatide tablets, as an anti-osteoporosis drug, have stability involving multiple dimensions such as chemical, physical and biological availability, which directly affects the efficacy and safety of the drug. The following is an analysis from the aspects of stability influencing factors, technical challenges and solutions:
The key factors affecting stability
Chemical degradation
Hydrolysis reaction: The peptide bonds in the teriparatide molecule are prone to breakage in a humid and hot environment, generating inactive degradation products. For example, in the buffer solution with pH 7.4, the half-life of teriparatide significantly shortens with the increase of temperature, and obvious degradation occurs within just a few hours at 40℃.
Oxidation reaction: Sulfur-containing amino acids such as methionine and cysteine are prone to oxidation, leading to the loss of drug activity. The oxidation reaction rate is closely related to the oxygen concentration, light intensity and residual metal ions.
Deamidation reaction: Asparagine and glutamine residues are prone to deamidation under high temperature and high humidity conditions, generating isomers that affect the drug's binding ability to receptors.
Physical stability
Hygroscopicity: Teriparatide powder has strong hygroscopicity. When exposed to a high-humidity environment (relative humidity > 60%), it is prone to agglomeration and caking, resulting in a decrease in the uniformity of its content.
Crystal form transformation: The polycrystalline phenomenon may lead to changes in drug solubility and dissolution rate, thereby affecting bioavailability. For example, the solubility of amorphous teriparatide is higher than that of crystalline teriparatide, but its stability is poorer.
Mechanical stability: During the processes of tablet pressing, coating and transportation, tablets may crack or flake due to stress, affecting the accuracy of dosage.
Bioavailability stability
Gastrointestinal degradation: Teriparatide is prone to inactivation under the action of gastric acid and trypsin, and its oral bioavailability is less than 1%.
First-pass effect: Liver metabolism may further reduce the drug concentration, and the intestinal absorption efficiency needs to be improved through formulation technology.
Technical Challenges
Technical bottleneck of formulation
The loading rate of nanocarriers is low
Although nanocarriers such as liposomes and polymer micelles can improve drug stability, the loading rate of teriparatide is usually less than 10%, which is difficult to meet the clinical dosage requirements.
Poor controllability of enteric-coated materials
The pH sensitivity of enteric-coated materials (such as hydroxypropyl methylcellulose phthalate) varies greatly, which may lead to incomplete or premature release of the drug in the intestine.
The difficulty of large-scale production is high
The preparation process of nano-preparations (such as high-pressure homogenization and supercritical fluid technology) has high requirements for equipment, and it is difficult to ensure consistency between batches.
The storage and transportation conditions are harsh
Temperature sensitivity
Teriparatide tablets should be stored in a refrigerator at 2-8℃. Temperature fluctuations during transportation (such as interruption of the cold chain) may cause drug degradation.
Light influence
Ultraviolet rays can accelerate the oxidation of drugs, so light-blocking packaging materials (such as brown glass bottles and aluminum foil composite films) should be used.
Humidity control
High humidity environments (such as tropical regions) can easily cause tablets to absorb moisture. Desiccants (such as silica gel) need to be added to the packaging.
Long-term stability data is lacking
Limitations of the accelerated test
The current accelerated test conditions (40℃/75%RH) may not fully simulate the degradation path during the actual storage process, resulting in inaccurate prediction of the validity period.
The real-time stability study cycle is long
At least three years of data support for the validity period declaration is required, which prolongs the time for the drug to be marketed.
Solutions for enhancing stability
Chemical modification: By PEGylation or fatty acid modification, the hydrophilicity of the drug is reduced and its enzymatic hydrolysis is decreased. For example, the stability of PEG2000-modified teriparatide in simulated gastric juice is increased by three times.
Nanocrystalline technology: By fabricating drugs into nanocrystallines (with particle size < 200nm), solubility and stability can be significantly enhanced. The teriparatide nanocrystals prepared by the medium grinding method were placed at 40℃/75%RH for 6 months, and the content was still > 95%.
Eutectic technology: Forms eutectics with amino acids (such as arginine) to improve physical stability. The melting point of the teriparatide-arginine eutectic increases by 10℃ and its hygroscopicity decreases by 50%.
Intelligent packaging: Utilizing temperature and humidity indicator cards to monitor storage conditions in real time; Or use phase change materials (PCM) to maintain a stable temperature inside the package.
Moisture-proof packaging: Double aluminum blister packaging combined with desiccant can control the moisture content of tablets to less than 2%, significantly extending the validity period.
Light-blocking packaging: Use dark glass bottles or plastic bottles with added ultraviolet absorbers to reduce light degradation.
Cold chain logistics: Establish a full-process temperature control system and use temperature recorders to monitor the transportation process in real time.
Stability indication method: Develop a quantitative method for degradation products based on HPLC-MS to accurately evaluate the stability of drugs.
Patient education: Provide portable refrigerated bags to guide patients on the correct storage of medications.
Future Development Direction
New formulation technology
Oral polypeptide delivery system: Combining penetration enhancers (such as SNAC) with ph-responsive polymers to enhance the intestinal absorption of teriparatide.
3D printed tablets: Achieve layered drug release, first rapidly releasing part of the drug to relieve symptoms, and then continuously releasing to maintain therapeutic effect.
Stability prediction model
Machine learning: Training models with degraded data to predict stability under different conditions and accelerate formulation development.
Quantum chemical computing: Simulating the degradation pathways of drug molecules and guiding chemical modification strategies.
International standard unification
ICH guideline update: Promote the formulation of guidelines for the stability study of peptide drugs, clarifying the conditions for accelerated trials and long-term trials.
Global supply chain collaboration: Establish cross-border cold chain alliances to ensure the consistency of drug quality on a global scale.
Conclusion
The stability of teriparatide tablets is restricted by multiple factors such as chemical degradation, physical changes and bioavailability. To enhance its stability, it is necessary to optimize the formulation process, innovate packaging and strictly manage storage. In the future, with the development of nanotechnology, smart packaging and stability prediction models, the stability of teriparatide tablets is expected to be further enhanced, providing a safer and more effective treatment option for patients with osteoporosis. Meanwhile, international cooperation needs to be strengthened, unified standards formulated, and the accessibility of drugs on a global scale promoted.
FAQ
1. What is the difference between it and an injection?
The core component (PTH 1-34) is the same, but this is an oral tablet, which is more convenient to use and avoids the discomfort of daily subcutaneous injections.
2. What are the main advantages?
It is a "bone formation stimulant", which can directly stimulate the growth of new bones and significantly increase bone density and strength. It is particularly suitable for patients with severe osteoporosis and a high risk of fractures.
3. What should be noted when using it?
It is necessary to take the medication strictly as prescribed by the doctor. Common side effects that may occur include nausea and other gastrointestinal reactions. The treatment period is usually limited (such as 18-24 months), and after the treatment is completed, it is necessary to switch to other anti-osteoporosis drugs to maintain the therapeutic effect.
Hot Tags: teriparatide tablets, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale